glp-1 weight loss drug news november 2025 Pipeline Update: - Prime Therapeutics A second helping of weight-loss
Description
doi: 10.1038/npp.2016.246
*** This was reported as a composite of death from cardiovascular causes and hospital admission for heart failure
These include: Nausea: Often experienced during the initial weeks of treatment as the body adjusts
RetaLABS Retatrutide is available in 10mg, 20mg and 30mg lyophilised vials
4 , 5 Given their expanding use in populations with obesity, T2DM, and cardiovascular disease, a deeper understanding of their impact on BP is increasingly relevant
Because GLP-1s slow stomach emptying, many people find that they tolerate small, cold sips of the Replenisher better than large gulps
